TWYNEO CREAM
Fight acne fast
with the 2-in-1 that’s never been done
![Microencapsulation technology](/images/mt-logo-purple.png)
The rapid efficacy you demand and tolerability they deserve.1-4
FOR PATIENTS AGES 9 AND UP1
Acne's first-ever
.1% tretinoin & 3% BPO 2-in-11,2
The once-daily cream that finally unites 2 proven ingredients for a never-before-seen fixed-dose combination. Using microencapsulation technology, TWYNEO cream helps patients stay on track with rapid results and tolerability with transient effects over time.1-4
![Photo of TWYNEO cream box with bottle next to it.](/images/twyneo-bottle-box.png)
![Microencapsulation logo](/images/micro-animation.gif)
![Younger male teenager with visible acne smiling confidently at camera.](/images/section-img-1.png)
![Female teenager holding a bottle of TWYNEO cream playfully in front of her face.](/images/section-img-2.gif)
![Older male teenager smiling confidently at camera.](/images/section-img-3.png)
Don't let your patients break the bank fighting breakouts
DISCOVER SAVINGSBPO=benzoyl peroxide.
Noninflammatory lesion reduction at Week 2.3,4
References: 1. TWYNEO (tretinoin and benzoyl peroxide) cream, 0.1%/3% [Prescribing Information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2021. 2. Sol-Gel Technologies Ltd. Sol-Gel Technologies announces FDA approval of TWYNEO®. Sol-Gel Advanced Topical Therapy. July 27, 2021. Accessed August 20, 2021. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-announces-fda-approval-twyneor 3. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-65-04; May 28, 2020. 4. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-65-05; June 5, 2020.